SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC Bulletin Board: OLGX), a specialty pharmaceutical company developing innovative therapies for the treatment and prevention of musculoskeletal diseases, today announced that Philip J. Young, President and CEO of Osteologix, will present a corporate overview highlighting the Company’s Phase II Osteoporosis clinical trial, the STRONG Study, Friday, September 28 at 8:50 a.m. during the EQUITIES 2007 Transatlantic Conference to be held at to be held at the NASDAQ MarketSite in New York City. A live audio webcast and slide presentation will be available via the internet by visiting www.equitiesmagazine.com.
